Hackensack Meridian JFK’s chief of cardiology explains how alcohol, salty foods, and holiday excess can lead to dangerous ...
Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...
Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...
Edgewise Therapeutics (EWTX) announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, ...
The next evolution of truFlex fortifies its position as a versatile solution for rehabilitation with new applications in functional strength for the abdomen, arms, calves, glutes and thighs.
PregaTips on MSN

When contractions go wrong

Labour contractions are your body’s way of guiding your baby into the world. But when they become too intense, too frequent, or too weak to make progress, labour can go off rhythm. Hypertonic labour ...
1 Department of Cardiology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of ...
Abstract: Ballistocardiography (BCG) is a non-invasive method to assess cardiac activity by detecting body recoil in response to heart contractions and blood flow. Traditionally, BCG technology was ...
Background and objective Prior studies have suggested that patients with premature ventricular complexes (PVCs) may have an increased risk for atrial fibrillation (AF) and stroke. It is unclear ...
CCM devices are distinct from the implantable cardioverter defibrillators, or ICDs, that physicians use in some people with heart failure. While ICDs prevent fatal arrhythmias, CCM devices are ...
The Optimizer CCM system. [Image courtesy of Impulse Dynamics] Impulse Dynamics announced today that it raised more than $158 million in financing to support its heart failure treatment technology.